| HCA |
Report |
Q2 2026 Revenue |
BEAT |
pred ~$20.23B vs. cons ~$19.45B |
HIGH |
| HCA |
Report |
Q2 2026 Adjusted Diluted EPS |
BEAT |
pred ~$7.59 vs. cons ~$7.46 |
HIGH |
| HCA |
Report |
Q2 2026 Adjusted EBITDA Margin |
MISS |
pred ~19.9% vs. cons ~20.6% |
MEDIUM |
| HCA |
Guide |
FY2026 Diluted EPS Guidance |
UNCHANGED |
guide ~$29.60 (mid of $28.70-30.50) vs. cons ~$29.65 (FY2026) |
HIGH |
| HCA |
Guide |
FY2026 Adjusted EBITDA Guidance |
UNCHANGED |
guide ~$15.75B (mid of $15.4-16.1B) vs. cons ~$15.7B (FY2026) |
HIGH |
| HCA |
Guide |
FY2026 ACA Exchange Headwind Assumption |
UNCHANGED |
guide ~$1.1B (mid of $1.0-1.2B) vs. cons ~$1.1B already reset post-preannouncement (FY2026) |
MEDIUM |
| HCA |
Return |
Day-1 residual (stock − beta × S&P 500) |
+0.7% |
— |
LOW |
| HCA |
Return |
5-day cumulative residual |
-1.2% (FADE) |
With Q2 details and FY26 guidance already pre-announced on 7/14 (stock already down ~9%, consensus already reset), the call itself offers limited fresh surprise on the already-known numbers, so day-1 move should be muted/slightly positive on relief that nothing worse emerged. But over the following days, incremental color on the 2027 ACA exchange cliff (full EPTC expiration, no offsetting one-time Medicaid SPP catch-up expected to recur) likely prompts sell-side analysts to trim out-year (FY27) EPS estimates and price targets even without a fresh Q2 miss, producing a mild fade as the 'temporal vs. structural' debate tilts more structural in models. |
LOW |